July 15th 2025
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.
Quality of Life Sustained With Maintenance Olaparib Rechallenge in Platinum-Sensitive Ovarian Cancer
September 30th 2022Patient-reported outcome data from the phase 3b OReO/ENGOT-ov38 trial showed no significant effect on quality of life following rechallenge with maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer.
First-Line Olaparib/Bevacizumab Maintenance Combo Approved in China for HRD+ Advanced Ovarian Cancer
September 23rd 2022Olaparib and bevacizumab has been approved in China as a frontline maintenance treatment for patients with advanced homologous recombination deficiency–positive ovarian cancer based on results from the phase 3 PAOLA-1 trial.
Applications Submitted to FDA and EMA for Maintenance Rucaparib in Advanced Ovarian Cancer
September 14th 2022A supplement biologics license and a Type II variation were submitted to the FDA and European Medicines Agency, respectively, for first-line rucaparib in patients with advanced ovarian cancer.
First-Line Rucaparib Maintenance Improves PFS in Ovarian Cancer, Regardless of HRD Status
June 6th 2022The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.
Neoadjuvant Durvalumab Plus Tremelimumab Combo Elicits Response in Advanced Ovarian Cancer
April 14th 2022Data from the phase 2 KGOG 3046 trial revealed evidence of antitumor activity with the neoadjuvant chemoimmunotherapy regimen containing durvalumab and tremelimumab for patients with advanced-stage ovarian cancer.
Ursula A. Matulonis, MD, on Key Findings With Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
April 14th 2022Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.